SecBot SecBot
8-K ·Filed May 12, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001725160-26-000041
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The dose selection and ASPENOVA initiation are material de-risking events for the azenosertib program. The stock should re-rate on the clearer path to accelerated approval. Key catalysts to watch: DENALI Part 2 topline readout (YE 2026) and any interim data from ASPENOVA. Cash runway into late 2027 removes near-term financing risk. Monitor for potential partnership or co-development deals as the program advances.

DirectionBullish
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Zentalis reported Q1 2026 results with a net loss of $35.4M ($0.50/share), slightly better than the $0.52 consensus. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib in Cyclin E1-positive PROC, the first patient dosed in the Phase 3 ASPENOVA confirmatory trial, and the on-track DENALI Part 2 topline readout expected by year-end 2026. Cash of $211.8M provides runway into late 2027, funding execution through these pivotal milestones.

Key Financial Metrics

EPS
−$0.50
est −$0.52 · +3.9%
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Net loss of $35.4M ($0.50/share) for Q1 2026 vs $48.3M ($0.67/share) in Q1 2025, beat consensus EPS of -$0.52 by 4.5%
  • Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
  • Selected 400mg QD 5:2 as the pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim analysis
  • ASPENOVA Phase 3 confirmatory trial first patient dosed in May 2026, designed to support full approval
  • DENALI Part 2 topline readout on track for year-end 2026, with potential to support accelerated approval
  • Total operating expenses decreased to $37.9M from $45.6M in Q1 2025, partly due to absence of $7.8M restructuring charge
  • R&D expenses increased to $28.7M from $27.2M, driven by advancing DENALI and ASPENOVA trials
  • Pre-commercial launch preparedness activities initiated following dose selection

Financial Impact

Net loss improved by $12.9M YoY to $35.4M; cash burn of $34.1M in Q1 2026; EPS beat consensus by $0.02

net_losscash_positionoperating_expenses

Risk Factors

  • DENALI Part 2 topline data may fail to meet efficacy endpoints required for accelerated approval
  • ASPENOVA Phase 3 trial enrollment or results could disappoint, delaying full approval
  • Competition from other WEE1 inhibitors or emerging therapies in PROC could limit market opportunity
  • Cash burn rate may require additional financing before late 2027 if milestones are delayed
  • Safety profile at 400mg dose, while improved, still shows Grade 3+ adverse events including neutropenia (12.7%) and fatigue (12.1%)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001725160-26-000041
Document: zntlq12026corporatedeck.htm0001725160-26-000041
Document: zntl-20260512.htm0001725160-26-000041
Document: 0001725160-26-000041-index-headers.html0001725160-26-000041
Document: 0001725160-26-000041-index.html0001725160-26-000041
Document: 0001725160-26-000041.txt0001725160-26-000041
8-K Data (Synthetic)0001725160-26-000041

Track record

18 reports on ZNTL

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026